GlassScriptPhysician profile
Alan M Heller
NPI 1831204882
$10,150.43
in general payments reported to CMS, 2019-2025
22 companies · $2,702 in 2025
The $2,702 reported for 2025 was more than what 77% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $623 · 2021: $1,604 · 2022: $1,576 · 2023: $1,628 · 2024: $1,677 · 2025: $2,702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,006.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $4,492.28 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,591.55 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $865.46 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $387.23 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $338.80 | 2020-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $305.12 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $200.86 | 2023-2025 | |
| Lilly USA, LLC | $189.22 | 2024-2025 | Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $132.84 | 2024-2025 | Zoryve |
| Mylan Specialty L.P. | $112.88 | 2020-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $93.28 | 2021-2023 | Airduo Digihaler |
| Amgen INC. | $85.46 | 2022-2025 | Tezspire |
| Genentech USA, INC. | $63.54 | 2020-2025 | Xolair |
| Galderma Laboratories, L.P. | $61.07 | 2025 | Nemluvio |
| Kaleo, INC. | $51.50 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greer Laboratories, INC. | $37.76 | 2023 | Oralair |
| Verona Pharma, INC. | $30.74 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $25.06 | 2021 | |
| Philips North America LLC | $23.67 | 2021 | |
| Optinose US, INC. | $23.51 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $21.27 | 2025 | Zoryve |
| Botanix Sb INC | $17.33 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Heller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.